Abstract
The effects of flesinoxan, a potent and selective 5-HT1A agonist, were studied in two pilot studies in panic disorder patients to explore the role of 5-HT1A receptors in the mechanism of action of antipanic agents. This paper reports on the results of these two studies with flesinoxan. In study I, using a single-blind crossover design, five patients were treated for 1 week with placebo, 4 weeks with flesinoxan (up to 2.4 mg per day), and 2 weeks with placebo. In study II, 15 patients were enrolled in a double-blind, three-armed study with placebo and two dosages of flesinoxan. After a single-blind placebo run-in phase of 1 week, patients were treated for 8 weeks with placebo, 0.6 or 1.2 mg/day flesinoxan. In pilot study I patients’ condition worsened during the 4-week flesinoxan treatment period. Anxiety was frequently reported as an adverse event. Symptoms returned to the pre-treatment level during the 2-week placebo washout period. In pilot study II, no treatment effects in either group were observed. Anxiety as an adverse event was less prominent than in the first pilot study. A lowering of mood was seen in some patients. The sample sizes of these two pilot studies are too small to draw firm conclusions on the efficacy of flesinoxan in panic disorder, but the present data are not encouraging in this respect. The worsening of symptoms seen with the highest dose of flesinoxan is intriguing and might give a clue to the understanding of the mechanism underlying similar effects seen with antidepressants in panic disorder patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
American Psychiatric Association (1987) Diagnostic and statistic manual of mental disorders. 3rd edn. revised. Washington APA, DC
Bel N, Artigas F (1991) Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: in vivo microdialysis study. Eur J Pharmacol 229:101–103
Borison RL, Albrecht JW, Diamond BI (1990) Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol Bull 26:207–210
Bradford LD, Stevens G (1994) Double-blind placebo controlled fixed does studies of flesinoxan in generalized anxiety disorders. Abstract of the American College of Neuropsychopharmacology, Puerto Rico, p 167
Briley M, Chopin P, Moret C (1991) The role of serotonin in anxiety: behavioural approaches. In: Briley M, File SE (eds) New concepts in anxiety. MacMillan, London, pp 56–73
Chaput Y, Blier P, de Montigny C (1988) Acute and long-term effects of antidepressant serotonin (5-HT) uptake blockers on the efficacy of 5-HT neurotransmission. Electrophysiological studies in the rat. Adv Biol Psychiatry 17:1–17
Chaput Y, de Montigny C, Blier P (1991) Presynaptic and postsynaptic modifications of the serotonergic system by long-term administration of antidepressant treatments. Neuropsychopharmacology 5:219–229
De Montigny C, Blier P (1992) Electrophysical properties of 5-HT-1A receptors and 5-HT-1A agonists. In: Stahl S, Gastpar M, Keppel Hesselink JM et al. (eds) Sorotonin 1A receptors in depression and anxiety. Raven Press, New York, pp 83–98
Den Boer JA, Westenberg HGM (1988) Effects of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Pshchopharmacol 3:59–74
Den Boer JA, Westenberg HGM (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102:85–94
Den Boer JA, Westenberg HGM, Kamerbeek WDJ, Verhoeven WMA, Kahn RS (1987) Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 2:21–32
De Vry J (1995) 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121:1–26
Frazer GA, Lapierre YD (1987) The effect of buspirone on panic disorder: a case report. J Clin Psychopharmacol 7:118–119
Fux M, Taub M, Zohar J (1993) Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. Acta Psychiatr. Scand 88: 235–237
Grof P, Joffe R, Kennedy S, Persad E, Syrotiuk J, Bradford D (1993) An open study of oral flesinoxan, a 5-HT-1A receptor agonist, in treatment-resistant depression. Int Clin Psychopharmacol 8:167–172
Guy W (1976) ECDEU Assessment manual for psychopharmacology. US Dept of Health, Education and Welfar, Rockville, Maryland, pp 337–340
Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55
Harto NF, Branconnier RJ, Spera KF (1988) Clinical profile of gepirone: a non-benzodiazepine anxiolytic. Psychopharmacol Bull 24:154–160
Invernizzi R, Belli S, Samamanti R (1991) Citalopram’s ability to increase the extracellular concentration of serotonin in the dorsal raphe prevents the drug’s effect in the frontal cortex. Brain Res 584:322–325
Invernizzi R, Bramante M, Samamanti R (1994) Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1A receptors. Eur J Pharmacol 260:243–246
Johnston DG, Troyer IE, Whitstett SF (1988) Clomipramine in the treatment of agoraphobic woman: Biol Psychiatry 25:101
Kahn RS, Westenberg HGM, Verhoeven WMA, Gispen-De Wied CC (1987) Effects of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 2:23–45
Kahn RS, Wetzler S, Van Praag HM, Asnis GM (1988a) Behavioral indications of serotonin receptor hypersensitivity in patients with panic disorder. Psychiatry Res 25:101–104
Kahn RS, Wetzler S, Van Praag HM, Asnis GM (1988b) Neuroendocrine evidence for serotonin receptor hypersensitivity in patients with panic disorder. Psychopharmacology 96:360–364
Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991) Anxiogenic effects ofm-CPP in patients with panie disorder—comparison to caffeïne’s anxiogenic effects. Biol Psychiatry 30: 973–984
Lesch KP, Wiesmann M, Hoh A, Muller T, Disselkamp-Tietze J, Osterheider M, Schulte HM (1992) 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 106:111–117
Mavissakalian M (1986) The fear questionnaire: a validity study. Behav Res Ther 24:83–85
Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 34:382–389
Pecknold JC (1994) Serotonin 5-HT-1A agonists: a comparative review. CNS Drugs 2 [3]:234–251
Pecknold JC, Matas M, Howarth BG (1989) Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry 34:766–774
Pecknold JC, Luthe L, Scott-Fleury MH, Jenkins S (1993) Gepirone in the treatment of panic disorder: an open study. J Clin Psychopharmacol 13[2]:145–149
Pohl R, Balon R, Yeragani VK, Gershon S (1989) Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 22 [suppl. 1]:60–67
Rickels K, Weisman K, Norstad N (1989) Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 43:81–86
Robinson DS, Shrotriya RC, Alms DR, Messina M, Andary J (1989) Treatment of panic disorder: nonbenzodiazepine anxiolytics, including buspirone. Psychopharmacol Bull 25[1]: 21–26
Schipper J, Tulp MTM, Berkelmans B, Mos J, Van der Heijden JAM, Olivier B (1991). Preclinical pharmacology of flesinoxan: a potential anxiolytic and antidepressant drug. Hum Psychopharmacol 6:53–61
Schweizer E, Rickels K (1988) Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate. J Clin Psychopharmacol 8:303
Sharp T, Bramwell SR, Grahame-Smith DG (1991). 5-HT1 agonists reduce 5-HT release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 96:283–290
Sheehan D, Raj AB, Harnett Sheehan K, Soto S (1988) The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacol Biochem Behav 29:815–817
Sheehan D, Raj A, Sheehan K, Soto S (1990) Is buspirone effective for panic disorder? J Clin Psychopharmacol 10:3–11
Sheehan D, Raj A, Harnett Sheehan K, Soto S, Knapp E (1993) The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr. Scand 88:1–11
Snaith RP, Baugh SJ, Clayden AD, Husain A, Sipple MA (1982) The clinical anxiety scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 141:518–523
Targum SD, Marshall LE (1989) Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28:295–306
Westenberg HGM, Den Boer JA (1994) The neuropharmacology of anxiety; a review on the role of serotonin. In: Den Boer JA, Sitsen JMA (eds) Handbook of depression and anxiety; a biological approach. Marcel Dekker. New York, Basel, Hong Kong, pp 405–446
Zitrin C, Klein D, Woerner M, Ross D (1983) Treatment of phobias. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 40:125–138
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Vliet, I.M., Westenberg, H.G.M. & den Boer, J.A. Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology 127, 174–180 (1996). https://doi.org/10.1007/BF02805991
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02805991